Novo Nordisk Wegovy marketing and ethical scrutiny

Novo Nordisk is facing regulatory and ethical scrutiny regarding the marketing and patient support strategies for its weight-loss medication, Wegovy.

In Denmark, the Ethical Committee for the Pharmaceutical Industry (Enli) fined the company 45,000 DKK plus VAT following a partnership with Falck. The committee ruled that providing patients with free specialist advice on diet and lifestyle, funded by Novo Nordisk, violated ethical rules. The ruling suggested the arrangement could act as a promotional measure by relieving doctors of patient management tasks and raised concerns regarding the exchange of patient data. Novo Nordisk has since terminated the partnership.

In the United States, the company is navigating FDA scrutiny over its advertising. The FDA previously flagged television advertisements for being “false or misleading,” specifically objecting to slogans like “live lighter” that implied superior weight loss results without sufficient data. In response to these pressures, Novo Nordisk has adjusted its digital marketing, transitioning from terms like “anti-obesity” to “weight loss” and increasingly referring to users as “customers” rather than “patients.”